Compare ORMP & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORMP | IMNM |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.6M | 2.5B |
| IPO Year | 2010 | 2020 |
| Metric | ORMP | IMNM |
|---|---|---|
| Price | $4.13 | $18.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $35.19 |
| AVG Volume (30 Days) | 136.7K | ★ 1.4M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | ★ 6.04% | N/A |
| EPS Growth | ★ 412.50 | 51.40 |
| EPS | ★ 2.76 | N/A |
| Revenue | $2,000,000.00 | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,803.97 |
| P/E Ratio | $1.50 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $2.09 | $14.64 |
| 52 Week High | $5.47 | $30.06 |
| Indicator | ORMP | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 36.24 | 34.57 |
| Support Level | $3.91 | $17.83 |
| Resistance Level | $4.22 | $23.48 |
| Average True Range (ATR) | 0.16 | 0.99 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 35.04 | 30.57 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.